Linerixibat (GSK2330672) Phase 2b Results

Linerixibat (GSK2330672) Phase 2b Results

Linerixibat (GSK2330672) Phase 2b Results

Linerixibat (GSK2330672), a drug that is being developed for PBC patients who experience itchiness, has recently published Phase 2b results.  This is promising news for patients who are suffering from itchiness (pruritus) which is one of the main symptoms of Primary Biliary Cholangitis. Read more here.

shares